文献速递糖尿病

瑞典成人糖尿病亚组的合并症与死亡率:最长14年前瞻性队列随访

Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-11-14

BACKGROUND: Subgroups of adult-onset diabetes, namely severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), and mild obesity-related diabetes (MOD) or mild age-related (MARD) diabetes, have been defined with clinica…

要点

  • SIRD虽血糖不高,但肾病、心梗、房颤、心衰和脂肪肝风险显著升高
  • SAID和SIDD诊断时及随访中HbA1c最高,视网膜病变和神经病变风险最高

核心结论

  • 糖尿病亚组可反映长期结局并指导新诊断患者的治疗与随访,SIRD为传统血糖指标难以识别的高危亚组。

研究设计与样本

  • 以MARD为对照,用logistic回归和Fine-Gray比例风险回归分析患病及新发合并症。

临床怎么用

  • 对新诊断糖尿病患者可依据临床变量进行亚组划分,以识别高危人群并个体化安排治疗与随访。
  • SIRD应作为重点筛查对象,关注肾脏、心血管、心衰和脂肪性肝病风险,即使血糖未达传统风险阈值。

局限性

  • 研究为瑞典人群队列,结论外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subgroups of adult-onset diabetes, namely severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), and mild obesity-related diabetes (MOD) or mild age-related (MARD) diabetes, have been defined with clinical variables and a machine-learning approach. Our aim was to describe their long-term outcomes and mortality. METHODS: In this prospective cohort study in Sweden, we used data from two subsets of the All New Diabetics in Scania (ANDIS) project cohort of individuals diagnosed with diabetes at regional care centres and enrolled within 1 year of diagnosis. Included participants were 18 years or older, did not have pancreatitis, and had complete data for cluster variables. We used GAD antibodies, Homeostasis Model Assessment 2 β cell and insulin resistance indices, BMI, HbA1c, and age at the diagnosis of diabetes to group individuals, and logistic and Fine-Gray proportional hazards regression to study prevalent and incident comorbidities, using the MARD group as comparator. FINDINGS: Between Jan 1, 2008, and Nov 3, 2016, for ANDIS1 and Nov 4, 2016, and April 6, 2022, for ANDIS2, a total of 25 590 were screened for eligibility, resulting in 19 076 participants being included in the analysis (9057 from ANDIS1 and 10 019 from ANDIS2; 11 171 men and 7905 women). The median follow-up time was 9·63 years (IQR 4·05) in ANDIS1 and 2·83 years (2·76) in ANDIS2. The SAID and SIDD subgroups had the highest HbA1c values at diagnosis and over time, and the highest age-adjusted and sex-adjusted risk of retinopathy (SAID adjusted hazard ratio [HR] 1·35 [95% CI 1·08-1·70]; SIDD 2·11 [1·82-2·44]) and neuropathy (2·58 [1·87-3·56]; 2·13 [1·69-2·70]). At the diagnosis of diabetes, SIRD had the highest prevalence of hypertension (2336 [69·8%] of 3348) and dyslipidaemia (1484 [44·4%]), and kidney (366 [10·9%]), cardiovascular (1026 [30·6%]), and steatotic liver disease (38 [1·1%]). Despite large differences in HbA1c, both SIDD and SIRD had an increased risk of incident kidney disease, including kidney failure (SIDD adjusted HR 2·94 [1·69-5·09]; SIRD 3·41 [2·06-5·64]), and myocardial infarction (1·44 [1·13-1·82]; 1·51 [1·22-1·87]). SIRD and MOD had the highest risk of atrial fibrillation (adjusted HR 1·32 [1·13-1·54]; 1·58 [1·26-1·98]). The risk of stroke was only increased in SIDD (adjusted HR 1·32 [1·07-1·62]), and steatotic liver disease (3·29 [2·32-4·66]) and heart failure (1·55 [1·34-1·79]) in SIRD. SIDD, SIRD, and MOD had the highest risk of total mortality (adjusted HRs 1·44-1·52) even after adjustment for established risk factors (age, sex, BMI, hypertension, LDL, and smoking), largely driven by cardiovascular mortality. INTERPRETATION: Diabetes subgroups could inform on outcomes, as well as guide treatment and follow-up needed for newly diagnosed individuals with diabetes. SIRD stands out as a high-risk subgroup that is not identified by conventional glycaemia-based risk factors, but bears risk of early onset end-organ damage and would benefit from identification and treatment before the diagnosis of diabetes. FUNDING: Swedish Research Council, Avtal om Läkarutbildning och Forskning Swedish government grants, Diabetes Wellness Sweden, the Swedish Heart and Lung Foundation, the Crafoord Foundation, the Swedish Diabetes Foundation, the Novo Nordisk Foundation, the Bo and Kerstin Hjelt Foundation, the Albert Påhlsson Research Foundation, Vinnova, and AstraZeneca.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Asplund O, Thangam M, Prasad RB, et al. Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden. Lancet Diabetes Endocrinol. 2025. PMID: 41248671. doi:10.1016/S2213-8587(25)00283-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。